Furthermore, platinum-based chemotherapy significantly decreased OS (p = 0.03) and progression-free survival (p = 0.01) for nine patients with loss of ARID1A expression compared to those with positive ARID1A expression in a cohort of 60 patients with epithelial ovarian cancer diagnosed at stages I to IV [68]. This evidence concerns the gene ARID1A and ovarian carcinoma.